PAIS 2:对乙酰氨基酚治疗卒中随机双盲安慰剂对照试验
PAIS 2 为多中心随机双盲安慰剂对照试验,计划纳入1500例发病12小时内急性缺血性卒中或脑出血患者,因招募慢和资金缺乏提前终止,实际纳入256例。对乙酰氨基酚每日6 g连用3天对3个月功能结局无影响(校正共同比值比1.15,95%CI 0.74-1.79),严重不良事件数无差异。高剂量对乙酰氨基酚似安全,但对功能结局的作用仍不确定,仍需大型试验。
要点
- 急性卒中后早期高热与不良结局相关,亚组分析曾提示对乙酰氨基酚可能改善≥36.5°C患者功能结局。
- 本研究因招募慢和资金缺乏提前终止,仅纳入256例,未证实对乙酰氨基酚对3个月功能结局的获益。
- 高剂量对乙酰氨基酚(每日6 g连用3天)似安全,严重不良事件数与安慰剂无差异。
核心结论
- 高剂量对乙酰氨基酚似安全,但其对急性卒中功能结局的作用仍不确定,仍需大型试验验证。
研究设计与样本
- PAIS 2为多中心、随机、双盲、安慰剂对照临床试验,计划纳入1500例发病12小时内急性缺血性卒中或脑出血患者。
- 因招募慢和资金缺乏提前终止,实际纳入256例,其中136例(53%)分配至对乙酰氨基酚组。
- 对乙酰氨基酚每日6 g或匹配安慰剂连用3天,主要结局为3个月改良Rankin量表功能结局,采用多变量有序logistic回归分析。
主要发现
- 对乙酰氨基酚对功能结局无影响,校正共同比值比1.15(95%CI 0.74-1.79)。
- 严重不良事件数无差异:对乙酰氨基酚组35例(26%),安慰剂组28例(24%)。
关键数值与推荐
- 对乙酰氨基酚每日剂量6 g,连用3天。
- 主要结局为3个月改良Rankin量表评估的功能结局。
- 校正共同比值比1.15(95%CI 0.74-1.79)。
- 严重不良事件:对乙酰氨基酚组35例(26%)vs 安慰剂组28例(24%)。
临床怎么用
- 高剂量对乙酰氨基酚在急性卒中早期使用似安全,但现有证据不足以支持其改善功能结局。
- 对发病12小时内伴体温≥36.5°C的急性卒中患者,对乙酰氨基酚的常规使用仍需等待大型试验结果。
局限性
- 研究因招募慢和资金缺乏提前终止,样本量仅256例,远低于计划的1500例。
- 样本量小导致检验效能不足,功能结局效应估计不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Subfebrile body temperature and fever in the first days after stroke are strongly associated with unfavorable outcome. A subgroup analysis of a previous trial suggested that early treatment with paracetamol may improve functional outcome in patients with acute stroke and a body temperature of ≥36.5°C. In the present trial, we aimed to confirm this finding. METHODS: PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) was a multicenter, randomized, double-blind, placebo-controlled clinical trial. We aimed to include 1500 patients with acute ischemic stroke or intracerebral hemorrhage within 12 hours of symptom onset. Patients were treated with paracetamol in a daily dose of 6 g or matching placebo for 3 consecutive days. The primary outcome was functional outcome at 3 months, assessed with the modified Rankin Scale and analyzed with multivariable ordinal logistic regression. Because of slow recruitment and lack of funding, the study was stopped prematurely. RESULTS: Between December 2011 and October 2015, we included 256 patients, of whom 136 (53%) were allocated to paracetamol. In this small sample, paracetamol had no effect on functional outcome (adjusted common odds ratio, 1.15; 95% confidence interval, 0.74-1.79). There was no difference in the number of serious adverse events (paracetamol n=35 [26%] versus placebo n=28 [24%]). CONCLUSIONS: Treatment with high-dose paracetamol seemed to be safe. The effect of high-dose paracetamol on functional outcome remains uncertain. Therefore, a large trial of early treatment with high-dose paracetamol is still needed. CLINICAL TRIAL REGISTRATION: URL: http://www.trialregister.nl. Unique identifier: NTR2365.
引用
- de Ridder IR, den Hertog HM, van Gemert HM, et al. PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial. Stroke. 2017. PMID: 28289240. doi:10.1161/STROKEAHA.116.015957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。